Eris vs Emcure vs Lupin: Which Stock Should You Track
- October 7, 2026
- Posted by: Chaitanya Auti
- Category: Market
Eris Lifesciences PE 26.27, mkt cap Rs 17,490 crore. Emcure Pharmaceuticals PE 36.22, mkt cap Rs 36,902 crore. Lupin PE 17.28, mkt cap Rs 95,939 crore.
Quick Answer
Eris Lifesciences vs Emcure Pharmaceuticals vs Lupin is a side-by-side comparison of three companies from the Pharma Formulations space. On this comparison, Eris Lifesciences carries a market capitalisation of about Rs 17,490 crore against Rs 36,902 crore for Emcure Pharmaceuticals and Rs 95,939 crore for Lupin, with return on equity of 15.87%, 18.67% and 23.76% respectively. Each company’s numbers are presented here without a declared better pick, since the right stock depends on an investor’s own criteria.
Eris Lifesciences vs Emcure Pharmaceuticals vs Lupin starts with the core numbers most investors compare within the Pharma Formulations segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of October 2026 and will shift with daily price moves.
All three names sit in the Pharma Formulations bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.
Click Here – Get Free Investment Predictions
Eris Lifesciences, Emcure Pharmaceuticals and Lupin: Company Overview
Eris Lifesciences is a listed Indian company in the Pharma Formulations space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Emcure Pharmaceuticals is a listed Indian company in the Pharma Formulations space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Lupin is a listed Indian company in the Pharma Formulations space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Eris Lifesciences vs Emcure Pharmaceuticals vs Lupin: Valuation and Profitability Snapshot
| Metric | Eris Lifesciences | Emcure Pharmaceuticals | Lupin |
|---|---|---|---|
| Market Cap (approx.) | Rs 17,490 crore | Rs 36,902 crore | Rs 95,939 crore |
| PE Ratio (TTM) | 26.27 | 36.22 | 17.28 |
| PB Ratio | 4.48 | 7.45 | 4.27 |
| Return on Equity (ROE) | 15.87% | 18.67% | 23.76% |
| EPS (TTM, Rs) | 47.98 | 53.71 | 121.39 |
| Dividend Yield | 0.57% | 0.18% | 0.86% |
| Debt to Equity | 0.60 | 0.31 | 0.29 |
| Book Value per Share (Rs) | 281.30 | 260.93 | 490.90 |
Check the Univest Screener for Live Data
On valuation, Eris Lifesciences trades at a PE of 26.27 and a PB of 4.48, Emcure Pharmaceuticals at a PE of 36.22 and a PB of 7.45, while Lupin trades at a PE of 17.28 and a PB of 4.27. On return on equity, the three post 15.87%, 18.67% and 23.76% respectively, and on dividend yield they stand at 0.57%, 0.18% and 0.86%.
Eris Lifesciences vs Emcure Pharmaceuticals vs Lupin: Latest Quarterly Results
| Company | Latest Quarter Revenue | Latest Quarter Net Profit | YoY Change (Revenue) | QoQ Change (Revenue) |
|---|---|---|---|---|
| Eris Lifesciences | Rs 875.64 crore | Rs 143.32 crore | +12.9% | +15.4% |
| Emcure Pharmaceuticals | Rs 2,582.52 crore | Rs 292.49 crore | +22.7% | +4.4% |
| Lupin | Rs 8,407.21 crore | Rs 1,416.98 crore | +32.5% | +10.4% |
Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter.
Download the Univest iOS App or Univest Android App to track Eris Lifesciences, Emcure Pharmaceuticals and Lupin live prices.
What Should Investors Look at Beyond These Numbers?
Beyond the metrics above, investors comparing these three pharma formulations names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and any sector-specific regulatory developments, since a single-quarter snapshot can shift quickly.
Conclusion
Eris Lifesciences vs Emcure Pharmaceuticals vs Lupin highlights how differently three companies in the same pharma formulations segment can score across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information as of October 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Eris Lifesciences vs Emcure Pharmaceuticals vs Lupin
What is the market cap difference between Eris Lifesciences, Emcure Pharmaceuticals and Lupin?
Ans. As of October 2026, Eris Lifesciences has a market cap of approximately Rs 17,490 crore, Emcure Pharmaceuticals is at approximately Rs 36,902 crore, and Lupin is at approximately Rs 95,939 crore.
Which of the three has the highest PE ratio?
Ans. Among Eris Lifesciences, Emcure Pharmaceuticals and Lupin, the PE ratios stand at 26.27, 36.22 and 17.28 respectively as of October 2026.
Which of the three has the highest ROE?
Ans. Eris Lifesciences, Emcure Pharmaceuticals and Lupin post ROE of 15.87%, 18.67% and 23.76% respectively as of October 2026.
Which of these three stocks pays the highest dividend yield?
Ans. Eris Lifesciences, Emcure Pharmaceuticals and Lupin carry dividend yields of 0.57%, 0.18% and 0.86% respectively.
What is the debt to equity ratio for Eris Lifesciences, Emcure Pharmaceuticals and Lupin?
Ans. Eris Lifesciences carries a debt to equity of 0.60, Emcure Pharmaceuticals of 0.31, and Lupin of 0.29.
Which of the three trades at the highest price to book value?
Ans. Eris Lifesciences, Emcure Pharmaceuticals and Lupin trade at price to book ratios of 4.48, 7.45 and 4.27 respectively.
Is one of Eris Lifesciences, Emcure Pharmaceuticals or Lupin better than the others?
Ans. This comparison does not declare one stock better than another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor’s own criteria and research.